Loading...
Please wait, while we are loading the content...
Similar Documents
Vildagliptin : novel pharmacological approach to treat Type 2 diabetes
| Content Provider | Semantic Scholar |
|---|---|
| Author | Ahrén, Bo |
| Copyright Year | 2007 |
| Abstract | 10.2217/14750708.5.1.79 © 20 Vildagliptin is an orally active inhibitor of the enzyme dipeptidyl peptidase-4. It prevents the inactivation of the gut hormone glucagon-like peptide-1, which results in increased endogenous levels of the hormone. This stimulates insulin secretion and inhibits glucagon secretion by increasing the glucose sensitivity of the pancreatic αand β-cells. A large body of evidence shows that vildagliptin improves glycemic control in subjects with Type 2 diabetes. Thus, vildagliptin reduces hemoglobin (Hb)-A1c by 0.8–1.1% from baseline levels of 7.7–8.5% as monotherapy in Type 2 diabetes. Furthermore, vildagliptin reduces HbA1c when used in combination therapy with metformin, a thiazolidinedione, a sulfonylurea or insulin. Moreover, vildagliptin is well tolerated, the risk of hypoglycemia is low and body weight is not increased during the treatment. Therefore, vildagliptin represents a novel pharmacological therapy for Type 2 diabetes. Its main potential is as an add-on therapy to metformin in patients with insufficient glycemic control, as an add-on to sulfonylurea and as a first-line treatment as monotherapy in patients who are intolerant to or have contraindications for metformin. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.openaccessjournals.com/articles/vildagliptin-novel-pharmacological-approach-to-treat-type-2-diabetes.pdf |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Add-ons for Firefox Baseline (configuration management) Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Glucagon-Like Peptide 1 Glucose Human body weight Hypoglycemia Metformin NSA product types Oral cavity Patients Pharmacology Sulfonylurea Compounds Thiazolidinediones glucagon secretion insulin secretion vildagliptin |
| Content Type | Text |
| Resource Type | Article |
